FDA clears MiniMed Fit tubeless insulin pump; Eversense 365 pairs with iLet; JAMA summit lays out obesity actions

Listen to this post
read by AI voices · all episodesThe Food and Drug Administration (FDA) cleared MiniMed Fit, the company's first tubeless insulin pump, for people with type 1 and type 2 diabetes ages 7 and older, MiniMed said Nov. 16. Senseonics and Beta Bionics launched pairing of the year-long Eversense 365 sensor with the iLet Bionic Pancreas, a JAMA summit report proposed obesity policy and care actions, and a trial of psychologist care in type 1 diabetes eased distress without a significant HbA1c change.
- FDA Nov 16, 2026MiniMed said Nov. 16 that the Food and Drug Administration (FDA) cleared MiniMed Fit for people with type 1 and type 2 diabetes ages 7 and older. The tubeless pump uses SmartGuard technology to adjust insulin delivery automatically and offers up to seven days of wear and a 300-unit insulin capacity controlled through a smartphone app, according to the company and Fierce Biotech. MiniMed said a phased U.S. rollout is expected to begin in spring 2027.Sources: MiniMed (via Finviz), Fierce Biotech
- FDA Nov 20, 2026The Food and Drug Administration (FDA) approved once-weekly somapacitan-beco (Sogroya) for children aged 2.5 years and older with growth failure associated with Turner syndrome, Novo Nordisk said Nov. 20. Results from the phase 3 REAL8 basket study supported the approval, according to Healio. It is the first and only once-weekly, long-acting growth hormone for children with Turner syndrome and the drug's fifth indication for a growth-related disorder, the company said.Sources: Novo Nordisk, Healio
- Research Nov 15, 2026In the phase 3 SURMOUNT-ADOLESCENTS trial, published in JAMA Nov. 15 and presented at ObesityWeek, 160 adolescents ages 12 to 17 with obesity were randomized to weekly tirzepatide or placebo with a lifestyle program. BMI fell 18.5% with tirzepatide and rose 0.5% with placebo at 72 weeks, an estimated treatment difference of -19.0 percentage points (95% CI -23.9 to -14.1), and 79.6% of the tirzepatide group lost at least 5% of BMI. Serious adverse events occurred in 7.4% versus 3.9%, Healio reported.
- Technology Nov 16, 2026Senseonics and Beta Bionics said Nov. 16 that the iLet Bionic Pancreas automated insulin delivery system now works with the Eversense 365 continuous glucose monitor, a single implantable sensor designed to last a full year. Eversense 365 is indicated for people with diabetes aged 18 years and older, according to the release, which did not announce a separate Food and Drug Administration clearance for the pairing. Beta Bionics is planning a full U.S. launch of its Mint patch pump in the first quarter of 2027, MedTech Dive reported.
- Policy Nov 17, 2026A JAMA Summit report on obesity prevention and care, published online Nov. 17 in JAMA, said nearly half of U.S. adults and 1 in 5 U.S. children meet the medical definition of obesity. Its proposed actions include government policies on food production, labeling, marketing and school nutrition, payment reform to support comprehensive obesity treatment and development of multidisciplinary care models. The authors wrote that no single intervention will be enough.
- Research Nov 20, 2026In a multicenter, open-label randomized trial published online Nov. 20 in Diabetes Care, 151 adults with type 1 diabetes received care that added a diabetes-educated psychologist or conventional care. The HbA1c difference was not significant (mean difference -0.2%, 95% CI -0.6 to 0.2; P = .31), while diabetes distress fell more in the psychologist group (mean difference -0.2, 95% CI -0.4 to -0.03; P = .040).Sources: Diabetes Care, PubMed
The weekly innovation roundup for endocrinology, published every Sunday for the week before; every item links to its sources. Latest endocrinology news · All specialties